This website uses cookies to ensure you get the best experience on our website.
Privacy Statement

ABOUT US

HCMED INNOVATIONS PROVIDES TOP DELIVERY PLATFORMS FOR INHALATION THERAPY USING MESH TECHNOLOGY

Mission

Our mission as a CDMO focused on inhalation therapy is to create highly integrated drug nebulizer combination products for affordable-best-quality featuring nebulization of high value therapeutic drugs that include small molecule synthetics and large molecule biologics, as either solutions, suspensions, and even difficult-to-deliver high viscosity drugs.


In order to achieve optimal aerosol performance for a specific formulation, we closely work with our partners to tailor the components of our mesh technology in combination with each formulation, while also incorporating innovative solutions such as connectivity and breath actuation.


By combining the strength of Taiwan's world-class manufacturing industry and a well-established GMP certified manufacturing facility, our products have received approval by multiple health authorities and have been launched in selected regions.

Vision

We bring significant value to global pharma partners through a cost efficient and risk-minimized pathway, designing combination products that can provide great contribution in the respiratory field.

Company History

  • OCT.2014

    HCmed Innovations Foundation

  • SEPT.2016

    ISO 13485 & Pulmogine CE Mark Approval

  • APR.2017

    Deepro TFDA Approval

  • MAY.2020

    Pulmogine® NMPA Approval

  • JUL.2021

    Pulmogine® FDA 510(k) Approval

  • JUL.2022

    Pulmogine® was included in the Australian Register of Therapeutic Goods

  • OCT.2022

    Global expansion to UK/
    Opening of UK laboratory

MANAGEMENT TEAM

CEO
Jason Cheng
Chief Executive Officer (CEO) and founder of HCmed Innovations Co., Ltd. Jason Cheng has over 10 years of experience in inhalation medical devices. Prior to HCmed, he successfully led a design company specialized in the development of electrical systems for mesh nebulizers. Among his expertise, he is also highly familiar with quality design standards and procedures of medical devices. Jason founded HCmed Innovations as a professional firm in the inhaled drug-device combination field in 2014. Since then, he has led the HCmed team to design, develop, and manufacture highly effective mesh nebulizers, successfully partnering with top global pharmaceutical companies and launching HCmed’s products in selected regions.
COO
Leon Tsai
Chief Operating Officer (COO) of HCmed Innovations Co., Ltd. Leon Tsai has an extended trajectory of over 20 years in the development and manufacturing of medical devices. He has designed and developed several medical devices such as body fat monitors, sphygmomanometers, skin analyzers, and mesh nebulizers, experience that has provided him with vast knowledge on the design and requirements of medical equipment as well as regulatory affairs. In 2014, Leon Tsai and Jason Cheng founded HCmed Innovations to focus on the respiratory field. Currently, he serves as board director and COO, where he oversees the company’s operation, the development of new innovative devices, and the integrated system of drug-device combination developments.
CFO
Wooca Tu
Wooca Tu serves as the Chief Finance Officer (CFO) of HCmed. He possesses over 8 years of experience in finance auditing at KPMG. During his tenure at KPMG, he led teams in providing assurance services to companies across various industries. Joining HCmed in 2019, Wooca supports the company in capital market operations. He is also responsible for managing the company's financial, human resources, legal, IT, and administrative functions. Since 2019, Wooca led fundraising through Series A, Series B, and Series B+ rounds, boosting HCmed's market capitalization to over US$56 million.

R&D Director

Connie Chen, Ph.D.

Dr. Chen serves as the Director of Business Development and is responsible for establishing partnerships in the biotech industry and managing business sales at HCmed. She holds a Ph.D. in Biomedical Engineering from National Yang-Ming University. Her career began with assisting in the commercialization of academic subsidy programs by the National Science and Technology Council. In 2014, she founded NaviFus Corp. Since then, she has been actively involved in company fundraising, strategic collaborations, development in drug and medical device, and sales in the biotechnology industry.

HCmed UK Laboratory Director

Lucy Hardaker

Lucy joined HCmed Innovations Co. Ltd in May 2023 as Director, UK Operations & Laboratory. She brings over 20 years experience in in-vitro testing of medical devices with gas pathways, across the product life cycle from feasibility to launch and into pharma collaborations for drug-device combination products. Prior to this role, Lucy led the Aerosol Sciences team in the Respiratory Drug Delivery division at Philips. Lucy received her BSc (Hons) in Human Biology from Oxford Brooks University.

BOARD OF DIRECTORS

Chairman/CEO & Co-Founder

Jason Cheng

Chief Executive Officer (CEO) and founder of HCmed Innovations Co., Ltd. Jason Cheng has over 10 years of experience in inhalation medical devices. Prior to HCmed, he successfully led a design company specialized in the development of electrical systems for mesh nebulizers. Among his expertise, he is also highly familiar with quality design standards and procedures of medical devices. Jason founded HCmed Innovations as a professional firm in the inhaled drug-device combination field in 2014. Since then, he has led the HCmed team to design, develop, and manufacture highly effective mesh nebulizers, successfully partnering with top global pharmaceutical companies and launching HCmed’s products in selected regions.

COO/Board Director & Co-Founder

Leon Tsai

Chief Operating Officer (COO) of HCmed Innovations Co., Ltd. Leon Tsai has an extended trajectory of over 20 years in the development and manufacturing of medical devices. He has designed and developed several medical devices such as body fat monitors, sphygmomanometers, skin analyzers, and mesh nebulizers, experience that has provided him with vast knowledge on the design and requirements of medical equipment as well as regulatory affairs. In 2014, Leon Tsai and Jason Cheng founded HCmed Innovations to focus on the respiratory field. Currently, he serves as board director and COO, where he oversees the company’s operation, the development of new innovative devices, and the integrated system of drug-device combination developments.

Board Director / Representative of VIVO PANDA FUND, L.P.

Mahendra G. Shah, Ph.D.

Board Director of HCmed Innovations Co., Ltd., focused on formulation and drug-device combination products. Dr. Shah is a highly successful pharmaceutical entrepreneur and executive who has been at Vivo Capital since March 2010. He is also the founder and executive chairman of Semnur Pharmaceuticals. Dr. Shah currently serves as chairman of the board of Essentialis Therapeutics, board member of Biotie Therapies (NASDAQ: BITI), and a member of the board of trustees of St. John’s University. At the same time, he is also a board member and charter member of EPPIC and a charter member of TIE.

Board Director & Co-Founder

Simon Hsieh

Board Director of HCmed Innovations Co., Ltd., focused on production automation. Simon Hsieh is a creditable executive with vast experience in the mobile phone, display, and automation industries. He has previously served as VP at Manz AG, as well as direct of strategic planning at of QISDA and AUO. Simon currently focuses on the productions of respiratory medical devices and low-level laser therapeutic medical devices, leading the planning for implementation of automation systems at HCmed Innovations.

Board Director

William Chung

Board Director of HCmed Innovations Co., Ltd., focused on investment and management. Mr. Chung has more than 15 years of venture investment experience in the life science and biotech/pharmaceutical industry. He has served as VP in the Taiwan CIDC group, being in charge of healthcare and biotech related investment. Currently, he holds a position as CEO in Forward BioT Venture Capital, focusing on investment in pharmaceutical and healthcare sectors. He is actively involved in portfolio management and works with portfolio companies closely in providing operational and business development support. Mr. Chung received his B.S. and M.S. in Agricultural Chemistry from National Taiwan University. In addition, he studied for four years in the PhD program at Imperial College London and University of Cambridge, UK.

Board Director

Vera Wu, MBA

Vera Wu is a Partner in KyrMar Advisory Services focused on providing local and multinational biotech and pharmaceutical companies support in their go-to-market and market expansion strategies and business development support in Taiwan. Vera led the business development efforts for EirGenix’s global trastuzumab licensing and supply deal with Sandoz Pharmaceuticals. Ms. Wu relocated from New York City where she last worked as a senior leader at Pfizer for over ten years. While there, Ms. Wu held various commercial roles including US LOE Asset Lead with responsibility for $3.0B USD in sales. Ms. Wu was a founding member of Pfizer’s Biosimiliar team responsible for gaining approval and launching ELELYSO globally. As a member of the Pfizer Corporate Strategy and Innovation team, Ms. Wu advised Pfizer’s CEO and executive leadership team on strategic options for complex corporate level opportunities. Before joining Pfizer, Ms. Wu worked as a principal consultant in Business Consulting Services for IBM (formerly PriceWaterhouseCoopers). Ms. Wu received her Master of Business Administration (MBA) in Finance and Strategic Management at The Wharton School, University of Pennsylvania in Philadelphia, Pennsylvania, and a Bachelor of Electrical Engineering from the University of Delaware.

Independent Board Director

Shih-Hau Fang Professor

Education

  • Ph.D., Graduate Institute of Communication Engineering, National Taiwan University

Experience

  • Postdoc, Graduate Institute of Communication Engineering Center, National Taiwan University
  • Associate Professor, Department of Electronic Engineering, Yuan Ze University
  • President's Special Assistant, Yuan Ze University
  • Academia Sinica

Independent Board Director

Shine Cheng CPA

Education

  • B.S., Accounting/Physical Education, Fu Jen Catholic University

Experience

  • Deloitte
  • Lungyen Life Service Corporation, Ltd.
  • SHEICO Group. 
  • Adjunct Lecturer, Takming University

Independent Board Director

Dean Chou Lawyer

Education

  • B.S., Law, National Chung-Cheng University
  • EMBA, Soochow University

Experience

  • Legal, YI SHENG Group
  • Legal, First International Computer Group
  • Lawyer, JOHNSON AND PARTNERS

Independent Board Director

I-Chen Chen Doctor

Education

  • MD, Faculty of Medicine, Kaohsiung Medical College
  • Master's Program, Graduate Institute of Medicine, Kaohsiung Medical University
  • Ph.D., Graduate Institute of Medicine, Kaohsiung Medical University

Experience

  • Attending Physician, Department of Pediatrics, Kaohsiung Medical University Hospital
  • Director of Pediatrics, Kaohsiung Medical University Gangshan Hospital
  • Associate Professor, Department of Pediatrics, School of Medicine, Kaohsiung Medical University

STRATEGIC ADVISORS

Combination Development
Pravin Soni, Ph.D.
Pravin Soni is a consultant with over 30 years of experience. He excels in FDA interactions in drug, device, and combination medical product development, relating to CMC aspects. Pravin held the position of Vice President of Development at Alexza Pharmaceuticals, where he led the development of the novel Staccato inhalation drug delivery platform. Later, he served as senior VP and CTO at Elevation Pharmaceuticals, leading the development of a combination product using nebulized glycopyrrolate for the inhalation treatment of COPD. Pravin also co-founded Patara Pharma, which was subsequently acquired by Roivant Sciences and later spun off as Respivant Sciences, a Roivant Division. As the Executive VP of Respivant Sciences, he was responsible for a wide range of functions, including IP, Quality Assurance, Development, CMC-regulatory, Manufacturing, and scaling up the production of a drug-device combination product for the treatment of refractory cough in Idiopathic Pulmonary Fibrosis (IPF). Currently, Pravin holds the position of President at PharmaCRO. He earned his Ph.D. in Polymer Science and Engineering from Case Western Reserve University and holds an impressive sixty-three (63) patents.
Medical Advisor/Co-Founder
Shaogi Huang, M.D.
Dr. Shaogi Huang graduated from Chang Gung University College of Medicine with outstanding academic achievements, earning him the prestigious Dr. Tsungming Tu Foundation Excellence in Graduation Award. He completed his pediatric residency and cardiology research fellowship at Chang Gung Memorial Hospital in Linkou, Taiwan. Subsequently, he established the Huang Shao-Chi Clinic in Linkou, where he has been serving as the president. In 2014, Dr. Huang, along with three other co-founders, established HCmed Innovations. He serves as the company's Medical Advisor, providing clinical medical advice to the team and valuable insights from the medical field to enhance product development and market strategies.
Business Strategy
Scott Fleming
F. Scott Fleming is an accomplished pharmaceutical, drug delivery, and digital health executive with over 30 years of experience developing, bringing to market, and monetizing new therapeutics. He has vast experience in the inhalation therapy industry and co-founded specialty pharmaceutical and drug delivery systems company MicroDose Therapeutx. This company developed leading-edge digital inhalers and respiratory disease therapies. During his time at MicroDose, he negotiated numerous license agreements and joint ventures with major pharma and biotech partners. In July 2013, he sold the company to Teva Pharmaceuticals in a deal worth $165 million. Following the acquisition, he joined Teva’s Global Commercial Respiratory group, where he served as the global brand director for eConnectivity in Teva’s respiratory franchise for over three years. Scott's career encompasses various aspects, including business development, strategy, contract negotiations, sales & marketing, brand development, fundraising, and multiple director positions. He is also recognized as an inventor on over a dozen patents and has been published in multiple peer-reviewed journals. Currently, he resides in Amsterdam, the Netherlands.
Strategic Scientific Advisor
Gunilla Petersson, Ph.D.
Dr. Petersson has over 30 years experiences in Drug and Inhaled drug development. She served as Science & Innovation Director, Inhaled Drug Delivery, at AstraZeneca for almost 30 years, holding different line management and scientific expert roles linking formulations and devices, mainly for inhaled drug product development. She has also worked in technology development and scouting, product development and registrations of new products, competitor landscape, CMC industry consortia boards and working teams (EPAG, IPAC-RS) for 10 years, drug project due diligences and scientific marketing of AstraZeneca products. Dr. Petersson holds a PhD in Analytical Chemistry from Lund University (Sweden).

GLOBAL OPERATIONS

HCmed's headquarters and R&D Center are located in Taipei City, Taiwan, where we provide CDMO services including feasibility studies and device development for our pharmaceutical partners. Our company's GMP-certified manufacturing site is situated in Zhonghe, New Taipei City, Taiwan. In 2023, we expanded to our first overseas site in the UK, where we offer various testing services to our pharmaceutical partners .


Companies and institutions based in the US, Japan, China, and Taiwan are among our main local and foreign investors. HCmed Innovations is constantly expanding its partnership with pharmaceutical companies for combination product worldwide, aiming to deliver top-quality inhalation treatment to people around the world.

  • Functional Sites
  • Investors
  • Partners

UK: Subsidiary

More

Taipei City: Headquarters

More

New Taipei City: GMP

More

1：Taipei City: HeadquartersMore

2：New Taipei City: GMPMore

3：UK: Subsidiary More

1：VIVO Capital

2：Cathay Life Insurance｜Mega Bank

3：H&Q Asia Pacific

4：Formosa Lab｜Forward Bio｜CIDC｜Horizon

5：DCI Partners

1：AeroRx Therapeutics, USA

2：Ebenbuild, Germany